Seven-year Experience of a Primary Care Antiretroviral Treatment Programme in Khayelitsha, South Africa
Overview
Authors
Affiliations
Objectives: We report on outcomes after 7 years of a community-based antiretroviral therapy (ART) programme in Khayelitsha, South Africa, with death registry linkages to correct for mortality under-ascertainment.
Design: This is an observational cohort study.
Methods: Since inception, patient-level clinical data have been prospectively captured on-site into an electronic patient information system. Patients with available civil identification numbers who were lost to follow-up were matched with the national death registry to ascertain their vital status. Corrected mortality estimates weighted these patients to represent all patients lost to follow-up. CD4 cell count outcomes were reported conditioned on continuous virological suppression.
Results: Seven thousand, three hundred and twenty-three treatment-naive adults (68% women) started ART between 2001 and 2007, with annual enrolment increasing from 80 in 2001 to 2087 in 2006. Of 9.8% of patients lost to follow-up for at least 6 months, 32.8% had died. Corrected mortality was 20.9% at 5 years (95% confidence interval 17.9-24.3). Mortality fell over time as patients accessed care earlier (median CD4 cell count at enrolment increased from 43 cells/microl in 2001 to 131 cells/microl in 2006). Patients who remained virologically suppressed continued to gain CD4 cells at 5 years (median 22 cells/microl per 6 months). By 5 years, 14.0% of patients had failed virologically and 12.2% had been switched to second-line therapy.
Conclusion: At a time of considerable debate about future global funding of ART programmes in resource-poor settings, this study has demonstrated substantial and durable clinical benefits for those able to access ART throughout this period, in spite of increasing loss to follow-up.
Wondmagegn H, Birhanu A, Gebremickael A, Esubalew H, Birhanu M, Gembe M BMC Infect Dis. 2024; 24(1):1059.
PMID: 39334011 PMC: 11428338. DOI: 10.1186/s12879-024-09984-9.
Lujintanon S, Hausler H, Comins C, Mcingana M, Shipp L, Phetlhu D Ann Epidemiol. 2024; 92:8-16.
PMID: 38382770 PMC: 10981924. DOI: 10.1016/j.annepidem.2024.02.006.
Rautenberg T, Ng S, George G, Moosa M, McCluskey S, Gilbert R Value Health Reg Issues. 2023; 35:42-47.
PMID: 36863066 PMC: 10256267. DOI: 10.1016/j.vhri.2022.12.006.
Pascoe S, Fox M, Kane J, Mngadi S, Manganye P, Long L BMJ Open. 2022; 12(12):e065848.
PMID: 36549749 PMC: 9772682. DOI: 10.1136/bmjopen-2022-065848.
McLigeyo A, Wekesa P, Owuor K, Mwangi J, Isavwa L, Mutisya I AIDS Res Hum Retroviruses. 2022; 38(6):480-490.
PMID: 35229643 PMC: 9225829. DOI: 10.1089/AID.2021.0112.